{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"0","value":"0"},{"groupId":"OG001","spread":"0","value":"0"},{"comment":"Due to insufficient number of participants in this age group (only 1 participant), CV% could not be calculated.","groupId":"OG002","spread":"NA","value":"127.7"},{"comment":"Due to insufficient number of participants in this age group (only 1 participant), CV% could not be calculated.","groupId":"OG003","spread":"NA","value":"142.1"}]}],"title":"Infants and Toddlers (age<2yr; n=0; n=0; n=1; n=1)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"59.8","value":"313.9"},{"groupId":"OG001","spread":"99.2","value":"513.6"},{"groupId":"OG002","spread":"76.8","value":"429.1"},{"groupId":"OG003","spread":"93.7","value":"817.6"}]}],"title":"Children (age>=2 & <12yr; n=10; n=14; n=7; n=5)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"60.9","value":"305.8"},{"groupId":"OG001","spread":"25.3","value":"605.1"},{"groupId":"OG002","spread":"69.4","value":"1008.9"},{"groupId":"OG003","spread":"58.2","value":"547.8"}]}],"title":"Adolescents (age>=12 & <18yr; n=8; n=5; n=7; n=2)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0","value":"0"},{"comment":"Due to insufficient number of participants in this age group (only 1 participant), CV% could not be calculated.","groupId":"OG001","spread":"NA","value":"390.0"},{"groupId":"OG002","spread":"0","value":"0"},{"groupId":"OG003","spread":"0","value":"0"}]}],"title":"Above 18 years (n=0; n=1; n=0; n=0)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"58.6","value":"310.3"},{"groupId":"OG001","spread":"90.4","value":"527.8"},{"groupId":"OG002","spread":"86.2","value":"589.8"},{"groupId":"OG003","spread":"101.5","value":"594.4"}]}],"title":"Total"}],"denoms":[{"counts":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"20"},{"groupId":"OG002","value":"15"},{"groupId":"OG003","value":"8"}],"units":"Participants"}],"description":"PK is the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body. AUC(INF) is the area under the plasma concentration-time curve from time zero extrapolated to infinite time.","dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"Dasatinib 60 mg/m\\^2 QD, as long as clinical benefit was maintained.","id":"OG000","title":"Dasatinib 60 mg/m^2"},{"description":"Tablets, Oral; If necessary in participants who could not swallow, tablets were dispersed into 30 cc of 100% fruit juice with no preservatives (minute maid lemonade or orange juice or apple juice). Dasatinib 80 mg/m\\^2 QD, as long as clinical benefit was maintained.","id":"OG001","title":"Dasatinib 80 mg/m^2"},{"description":"Tablets, Oral; If necessary in participants who could not swallow, tablets were dispersed into 30 cc of 100% fruit juice with no preservatives (minute maid lemonade or orange juice or apple juice). Dasatinib 100 mg/m\\^2 QD, as long as clinical benefit was maintained.","id":"OG002","title":"Dasatinib 100 mg/m^2"},{"description":"Tablets, Oral; If necessary in participants who could not swallow, tablets were dispersed into 30 cc of 100% fruit juice with no preservatives (minute maid lemonade or orange juice or apple juice). Dasatinib 120 mg/m\\^2 QD, as long as clinical benefit was maintained.","id":"OG003","title":"Dasatinib 120 mg/m^2"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"All treated participants with plasma samples available. n=number of PK parameters included. Each participant could have more than 1 plasma profiles sampled, depending on the number of times the dose of dasatinib was escalated.","reportingStatus":"POSTED","timeFrame":"During Week 1 of Course 1, and any course in which dose escalation was performed (at pre-dose, and at 0.5, 1, 2, 4, 6, 8 and 24 hours).","title":"Dasatinib Plasma Pharmacokinetic Parameter: Area Under the Plasma Concentration Versus Time Curve From Time Zero Extrapolated to Infinite Time (AUC[INF]) by Dose Level and Age Group","type":"SECONDARY","unitOfMeasure":"ng.h/mL"}